EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies

Wenhui Zhang iD, Dorothy Cheung, Alice Fong, Logan Brooks iD, Michele A Grimbaldeston, Audrey Arjomandi, Xiaoying Yang, Ajit Dash, Hansen Wong, Jane R Parnes, Divya Mohan

Clinical and Translational Science · 2025-10 · 18 (10)

DOI: 10.1111/cts.70338 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 02.10.2025. Verfasst von Wenhui Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Interleukin-1 Receptor-Like 1 Protein, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, binds with high affinity to ST2, the interleukin‐33 receptor, thereby blocking ST2/interleukin‐33 binding and subsequent inflammatory cascades involved in inflammatory diseases. Here, we present three randomized, double‐blind, placebo‐controlled, Phase I studies evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of single‐ascending doses of astegolimab in healthy participants and patients with mild atopic asthma (NCT01928368), multiple‐ascending doses in healthy participants (NCT02170337), and single‐ascending doses in healthy Japanese and White adults. Overall, 152 participants were enrolled, randomized, and treated with single‐ or multiple‐ascending doses of astegolimab ( n = 112) or placebo ( n = 40) subcutaneously (2.1–560 mg) or intravenously (210 or 700 mg). No deaths, serious adverse events, or discontinuations due to adverse events occurred during the studies. No clinically meaningful differences in incidence of TEAEs were observed between treatment arms. Pharmacokinetic exposure increased more than dose proportionally over 2.1–420 mg for single‐ascending doses but were approximately dose proportional for single‐ and multiple‐ascending doses ≥ 70 mg following subcutaneous administration. No pharmacokinetic differences were observed based on ethnicity between Japanese and White participants following body weight adjustments. Incidence of antidrug antibodies to astegolimab in healthy participants in the single‐ and multiple‐ascending dose studies was 14%–23% and 33%–50% for subcutaneous and intravenous administration, respectively. Astegolimab was well tolerated in these Phase I studies with no safety concerns identified. Thus, further assessment of astegolimab in targeted patient populations was justified; the Phase IIb ALIENTO and Phase III ARNASA trials in patients with chronic obstructive pulmonary disease are ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAsthmaInterleukin-1 Receptor-Like 1 ProteinAntibodies, MonoclonalHumansMaleAdultFemaleDouble-Blind MethodMiddle AgedYoung AdultDose-Response Relationship, DrugInjections, SubcutaneousHealthy VolunteersAdolescentAdministration, Intravenous

Stichwörter der Autor:innen

monoclonal antibodiespharmacokineticsphase 1safety

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-1 Receptor-Like 1 ProteinIL1RL1 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, California, USA.
  • Amgen Inc., South San Francisco, California, USA.
  • Amgen Inc., Thousand Oaks, California, USA.

ORCID-Profile: Wenhui Zhang, Logan Brooks

Zitieren

APA

Zhang, W., Cheung, D., Fong, A., Brooks, L., Grimbaldeston, M. A., Arjomandi, A., Yang, X., Dash, A., Wong, H., Parnes, J. R., & Mohan, D. (2025). Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies. Clinical and Translational Science, 18(10). https://doi.org/10.1111/cts.70338

Vancouver

Zhang W, Cheung D, Fong A, Brooks L, Grimbaldeston MA, Arjomandi A, et al. Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies. Clinical and Translational Science. 2025;18(10). doi:10.1111/cts.70338

BibTeX
@article{Zhang2025,
  author = {Zhang, Wenhui and Cheung, Dorothy and Fong, Alice and Brooks, Logan and Grimbaldeston, Michele A and Arjomandi, Audrey and Yang, Xiaoying and Dash, Ajit and Wong, Hansen and Parnes, Jane R and Mohan, Divya},
  title = {Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {10},
  doi = {10.1111/cts.70338}
}
Kostenlos starten →